DF Dent & Co. Inc. Continues to Hold Position in Becton, Dickinson and Company (BDX)

DF Dent & Co. Inc. maintained its position in shares of Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,741 shares of the medical instruments supplier’s stock at the end of the first quarter. DF Dent & Co. Inc.’s holdings in Becton, Dickinson and were worth $319,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock worth $727,863,000 after buying an additional 242,081 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after buying an additional 39,362 shares in the last quarter. Finally, Fundsmith LLP raised its stake in shares of Becton, Dickinson and by 3.2% in the first quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock worth $421,291,000 after buying an additional 71,691 shares during the period. Hedge funds and other institutional investors own 75.57% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) opened at 197.69 on Friday. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The stock has a 50 day moving average price of $199.72 and a 200 day moving average price of $188.69. The firm has a market cap of $44.99 billion, a PE ratio of 57.25 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period in the prior year, the business earned $2.35 earnings per share. The business’s quarterly revenue was down 5.1% on a year-over-year basis. Equities research analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.48%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

TRADEMARK VIOLATION WARNING: This article was first posted by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/df-dent-co-inc-continues-to-hold-stake-in-becton-dickinson-and-company-bdx-updated.html.

A number of equities research analysts have weighed in on BDX shares. Zacks Investment Research lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Evercore ISI raised Becton, Dickinson and from an “in-line” rating to an “outperform” rating and lifted their target price for the company from $186.00 to $200.00 in a research report on Monday, April 24th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their price target for the company from $210.00 to $180.00 in a report on Friday, June 30th. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Finally, BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $195.79.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the sale, the vice president now owns 70,821 shares in the company, valued at approximately $13,171,289.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Nabil Shabshab sold 6,149 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total transaction of $1,240,622.24. Following the completion of the sale, the insider now owns 15,648 shares of the company’s stock, valued at approximately $3,157,140.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 57,631 shares of company stock valued at $11,112,178. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply